Home > Cardiology > HFA 2022 > Should ATTR-CM be added to differential diagnosis of patients with HF?

Should ATTR-CM be added to differential diagnosis of patients with HF?

Presented By
Dr Rocío Ruiz Hueso, University Hospital of Virgen Macarena, Spain
Conference
HFA 2022
Amyloidosis was determined to be the cause of heart failure (HF) in approximately 20% of the patients treated in the internal medicine departments of 24 Spanish hospitals. According to the authors, transthyretin amyloid cardiomyopathy (ATTR-CM) should be included in the differential diagnosis of elderly patients with HF and myocardial thickening. Dr Rocío Ruiz Hueso (University Hospital of Virgen Macarena, Spain) and colleagues aimed to assess the prevalence of cardiac amyloidosis (CA) in patients who had HF and were treated at the Internal Medicine departments of Spanish hospitals HF (PREVAMIC NCT04066452) [1]. They also compared patient profiles between those whose HF was caused by CA and those with another cause of HF. The observational, prospective, cross-sectional multicentre study included 453 patients with HF (≥65 years) who displayed left ventricula...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on